| Literature DB >> 30944297 |
Ning Xue1, Yi Fang1, Xiaoqiang Ding1, Li Wang1, Linghan Xu1, Xiaotian Jiang1, Xiaoyan Zhang1.
Abstract
BACKGROUND The aim of this study was to determine the risk factors for early chronic kidney disease (CKD) (GFR 60-89 ml/min/1.73 m²; CKD stage 2) in asymptomatic Chinese individuals undergoing routine health examination. MATERIAL AND METHODS This cross-sectional study enrolled 9100 individuals who received voluntary medical examinations between 10/01/2011 and 09/30/2017. Demographic data, clinical history, clinical examination, medication, smoking, alcohol, blood biochemistry, urinalysis, and carotid ultrasound were extracted from the medical records. All laboratory analyses were performed routinely. Multivariable logistic regression for factors predicting CKD stage 2 was performed. RESULTS A total of 9100 individuals were enrolled (age of 18-65 and 65.4% male). CKD stage 2 was found in 1989/9100 individuals (21.9%). Male gender (OR=6.711, 95%CI: 5.376-8.403, P<0.001), older age (OR=1.077, 95%CI: 1.068-1.086, P<0.001), hemoglobin levels (OR=1.051, 95%CI: 1.046-1.057, P<0.001), triglycerides levels (OR=1.174, 95%CI: 1.067-1.292, P=0.001), HDL-C (OR=0.539, 95%CI: 0.380-0.763, P<0.001), Lp(a) levels (OR=1.000, 95%CI: 1.000-1.001, P=0.03), and carotid atherosclerosis (OR=1.248, 95%CI: 1.005-1.550, P=0.045) were associated with CKD stage 2 among all subjects. Serum triglycerides levels were associated with CKD stage 2 in the 18-45 and 45-65 years of age subgroups. CONCLUSIONS Factors that are routinely assessed during routine health examinations (male gender, age, hemoglobin levels, triglycerides levels, HDL-C, Lp(a) levels, and carotid atherosclerosis) can help identify individuals at higher risk of having CKD stage 2. The Chinese dyslipidemia is characterized by high triglycerides and low HDL-C and occurs in young and middle-aged individuals. Those factors could help identify individuals at higher risk for CKD stage 2 and who could benefit from preventive treatments.Entities:
Mesh:
Substances:
Year: 2019 PMID: 30944297 PMCID: PMC6461005 DOI: 10.12659/MSM.913506
Source DB: PubMed Journal: Med Sci Monit ISSN: 1234-1010
Characteristics of the subjects.
| Baseline data | eGFR 60–89 ml/min/1.73 m2 (n=1989) | eGFR >90 ml/min/1.73 m2 (n=7111) | P |
|---|---|---|---|
| Gender, Male, n (%) | 1050 (52.8) | 4902 (68.9) | <0.001 |
| Age (years) | 48.00 [21.00–60.00] | 45.00 [18.00–60.00] | <0.001 |
| History of hypertension, n (%) | 537 (27.0) | 1621 (22.8) | <0.001 |
| History of diabetes mellitus, n (%) | 210 (10.6) | 752 (10.6) | 0.983 |
| History of coronary heart disease or stroke, n (%) | 138 (6.9) | 400 (5.6) | 0.028 |
| History of chronic kidney disease, n (%) | 95 (4.8) | 337 (4.7) | 0.945 |
| History of cancer, n (%) | 62 (3.1) | 139 (2.0) | 0.002 |
| Body mass index (kg/m2) | 24.28 [14.86–42.41] | 24.44 [14.33–45.52] | 0.091 |
| Hemoglobin (g/L) | 150.00 [81.00–194.00] | 142.00 [63.00–207.00] | <0.001 |
| Proteinuria, n (%) | 33 (1.7) | 141 (2.0) | 0.351 |
| Hematuria, n (%) | 64 (3.2) | 400 (5.6) | <0.001 |
| Blood uric acid (μmol/L) | 389.00 [124.00–821.00] | 331.00 [100.00–716.00] | <0.001 |
| Total cholesterol (mmol/L) | 4.84 [1.90–11.17] | 4.72 [1.83–14.70] | <0.001 |
| Triglycerides (mmol/L) | 1.61 [0.40–16.23] | 1.42 [0.31–21.56] | <0.001 |
| High-density lipoprotein cholesterol (mmol/L) | 1.14 [0.38–3.15] | 1.22 [0.28–10.70] | <0.001 |
| Low-density lipoprotein cholesterol (mmol/L) | 2.82 [0.33–8.64] | 2.68 [0.35–8.02] | <0.001 |
| Lipoprotein (a) (mg/dL) | 124.00 [0.00–2534.00] | 119.00 [0.00–4643.00] | 0.324 |
| Carotid atherosclerosis, n (%) | 172 (8.6) | 580 (8.2) | 0.482 |
Logistic regression analysis of factors predicting for eGFR of 60–89 ml/min/1.73 m2.
| Variables | OR | 95% CI | P |
|---|---|---|---|
| Male | 6.711 | 5.376–8.403 | <0.001 |
| Older age | 1.077 | 1.068–1.086 | <0.001 |
| History of hypertension (yes | 1.049 | 0.873–1.26 | 0.609 |
| History of diabetes mellitus (yes | 0.863 | 0.691–1.078 | 0.194 |
| History of coronary heart disease or stroke (yes | 1.057 | 0.836–1.338 | 0.642 |
| History of cancer (1=yes | 1.074 | 0.747–1.544 | 0.702 |
| Body mass index | 1.046 | 0.868–1.26 | 0.639 |
| Systolic blood pressure (high | 1.069 | 0.793–1.441 | 0.662 |
| Diastolic blood pressure (high | 1.052 | 0.753–1.47 | 0.768 |
| Hemoglobin | 1.051 | 1.046–1.057 | <0.001 |
| Triglycerides | 1.174 | 1.067–1.292 | 0.001 |
| High-density lipoprotein cholesterol | 0.539 | 0.38–0.763 | <0.001 |
| Low-density lipoprotein cholesterol | 0.955 | 0.726–1.256 | 0.74 |
| Lp(a) | 1.000 | 1.000–1.001 | 0.028 |
| Carotid atherosclerosis (yes | 1.248 | 1.005–1.550 | 0.045 |
Logistic regression analysis of factors predicting for eGFR of 60–89 ml/min/1.73 m2 in male and female subjects.
| Variables | Males | Females | ||||
|---|---|---|---|---|---|---|
| OR | 95% CI | P | OR | 95% CI | P | |
| Age | 1.073 | 1.058–1.089 | <0.001 | 1.085 | 1.072–1.097 | <0.001 |
| History of hypertension (yes | 1.6 | 1.078–2.373 | 0.02 | 0.914 | 0.74–1.129 | 0.404 |
| History of diabetes mellitus (yes | 0.936 | 0.599–1.463 | 0.773 | 0.836 | 0.645–1.084 | 0.177 |
| History of coronary heart disease or stroke (yes | 1.095 | 0.662–1.811 | 0.723 | 0.999 | 0.762–1.309 | 0.993 |
| History of hepatitis (yes | 0.808 | 0.587–1.112 | 0.191 | 0.988 | 0.821–1.188 | 0.895 |
| History of cancer (1=yes | 1.477 | 0.867–2.515 | 0.151 | 0.835 | 0.48–1.452 | 0.523 |
| Body mass index | 0.618 | 0.375–1.02 | 0.06 | 1.392 | 0.996–1.946 | 0.053 |
| Hemoglobin | 1.07 | 1.06–1.079 | < 0.001 | 1.031 | 1.024–1.038 | < 0.001 |
| Triglycerides | 1.443 | 1.065–1.955 | 0.018 | 1.229 | 1.078–1.401 | 0.002 |
| High-density lipoprotein cholesterol | 0.789 | 0.409–1.52 | 0.479 | 0.47 | 0.282–0.784 | 0.004 |
| Low-density lipoprotein cholesterol | 1.086 | 0.606–1.943 | 0.782 | 0.838 | 0.548–1.282 | 0.415 |
| Lp(a) | 1.000 | 1.000–1.001 | 0.225 | 1.001 | 1–1.001 | 0.006 |
| Carotid atherosclerosis (yes | 0.71 | 0.4–1.26 | 0.241 | 0.799 | 0.631–1.012 | 0.063 |
Logistic regression analysis of factors predicting for eGFR of 60–89 ml/min/1.73 m2 in subjects 18–45 and 45–65 years of age.
| Variables | 18–45 years | 45–65 years | ||||
|---|---|---|---|---|---|---|
| OR | 95% CI | P | OR | 95% CI | P | |
| Male gender | 10.526 | 7.143–15.625 | < 0.001 | 5.025 | 3.831–6.579 | < 0.001 |
| Older age | 0.988 | 0.654–1.492 | 0.953 | 1.194 | 0.974–1.463 | 0.088 |
| History of hypertension (yes | 1.039 | 0.555–1.943 | 0.906 | 1.247 | 0.965–1.612 | 0.092 |
| History of diabetes mellitus (yes | 0.968 | 0.282–3.33 | 0.959 | 1.161 | 0.77–1.751 | 0.476 |
| History of coronary heart disease or stroke (yes | 0.925 | 0.548–1.561 | 0.769 | 1.011 | 0.731–1.396 | 0.949 |
| History of chronic kidney disease (yes | 0.853 | 0.644–1.131 | 0.269 | --- | --- | --- |
| History of cancer (1=yes | 1.051 | 0.755–1.465 | 0.767 | 1.156 | 0.952–1.404 | 0.144 |
| Body mass index | 0.864 | 0.346–2.155 | 0.754 | 0.984 | 0.642–1.51 | 0.942 |
| Hemoglobin | 0.989 | 0.589–1.661 | 0.966 | 0.992 | 0.73–1.349 | 0.96 |
| Blood cholesterol | 0.895 | 0.64–1.253 | 0.52 | --- | --- | --- |
| Triglycerides | 1.389 | 1.042–1.851 | 0.025 | 1.193 | 1.000–1.423 | 0.0498 |
| High-density lipoprotein cholesterol | 0.994 | 0.755–1.309 | 0.965 | 0.875 | 0.718–1.068 | 0.189 |
| Low-density lipoprotein cholesterol | 0.89 | 0.624–1.271 | 0.521 | 0.838 | 0.654–1.073 | 0.161 |
| Lp(a) | 0.946 | 0.682–1.31 | 0.737 | 1.066 | 0.843–1.347 | 0.595 |
| Carotid atherosclerosis (yes | 1.76 | 0.751–4.125 | 0.194 | 1.495 | 1.063–2.103 | 0.021 |